terbutaline sulfate(redirected from Brethair)
Pharmacologic class: Selective beta2-adrenergic receptor agonist
Therapeutic class: Bronchodilator
Pregnancy risk category B
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors; inhibits release of hypersensitivity mediators, especially from mast cells
Injection: 1 mg/ml
Tablets: 2.5 mg, 5 mg
Indications and dosages
➣ Bronchospasm in reversible obstructive airway disease
Adults and children older than age 12: 0.25 mg subcutaneously, repeated in 15 to 30 minutes p.r.n., up to a maximum of 0.5 mg in 4 hours. Or 2.5 to 5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 15 mg/day in adults; 2.5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 7.5 mg/day in children.
• Renal impairment
• Tocolytic in preterm labor
• Hypersensitivity to drug, its components, or sympathomimetic amines
Use cautiously in:
• cardiovascular disorders, hypertension, arrhythmias, hyperthyroidism, diabetes mellitus, seizure disorders, glaucoma
• concurrent use of MAO inhibitors, tricyclic antidepressants, or beta-adrenergic blockers
• elderly patients
• breastfeeding patients.
• Inject subcutaneously into lateral deltoid.
CNS: tremors, anxiety, nervousness, insomnia, headache, dizziness, drowsiness, stimulation
CV: palpitations, chest discomfort, tachycardia
GI: nausea, vomiting
Skin: diaphoresis, flushing
Drug-drug. Beta-adrenergic blockers: blockage of bronchodilating effect
MAO inhibitors, tricyclic antidepressants: potentiation of terbutaline's adverse cardiovascular reactions
Other sympathomimetic amines: additive adverse cardiovascular reactions
• Monitor vital signs.
• Assess neurologic status.
• Tell patient he may take with or without food.
• Advise patient or parents to establish effective bedtime routine to minimize insomnia.
• Instruct patient or parents to space doses evenly during waking hours, to avoid taking drug at bedtime.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.
BricanylA beta-adrenergic receptor agonist used for patients with COPD.
Asthma, bronchitis, reversible bronchospasm.
Tremor, nervousness, palpitations, nausea, vomiting.